Athos Therapeutics is currently advancing two preclinical programs for patients with Ulcerative Colitis & Crohn’s Disease. Furthermore, Athos is pursuing additional discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases and cancer.
(Moderate-to-severe, anti-TNFA refractory & colonic disease)
(Moderate, anti-TNFA naive colonic & ileal disease)
(Moderate-to-severe, ileal CD)
(monotherapy or combo with cancer immunotherapy)